| Phase 11 trial |
|
Phase 1
|
NCT05653752 |
Dec 2022 → Dec 2026 expected |
breast cancer, non-small cell lung carcinoma |
MediLink Therapeutics (Suzhou) Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT07169994 |
Sep 2025 → Sep 2026 expected |
breast cancer, non-small cell lung carcinoma |
MediLink Therapeutics (Suzhou) Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT07202364 |
Aug 2025 → Aug 2026 overdue |
cervical cancer, colorectal cancer, non-small cell lung carcinoma |
MediLink Therapeutics (Suzhou) Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06439771 |
Apr 2024 → Jul 2026 overdue |
breast cancer |
MediLink Therapeutics (Suzhou) Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06107686 |
Dec 2023 → Nov 2026 expected |
breast cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma |
MediLink Therapeutics (Suzhou) Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT07416994 |
Mar 2026 → Aug 2028 expected |
non-small cell lung carcinoma |
MediLink Therapeutics (Suzhou) Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07461454 |
Mar 2026 → Dec 2027 expected |
breast cancer |
MediLink Therapeutics (Suzhou) Co., Ltd. |
Recruiting
|
No outcome recorded
|